Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast

Tuesday, May 16, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

OSLO, Norway, May 16, 2017 /PRNewswire/ --

Press Release no: 14/2017

Nordic Nanovector ASA (OSE:

NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will announce its first quarter 2017 results on Wednesday, 24th of May 2017.

A

presentation by Nordic Nanovector's senior management team will take place at 8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: NYLAND

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2017 from 7:00 am CET the same day.

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

CONTACT:

For further information, please contact:

IR enquiries:Tone Kvåle, Chief Financial OfficerCell: +47-91-51-95-76Email: [email protected]

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: [email protected] / [email protected]

This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-first-quarter-2017-results-presentation-and-webcast,c2266801

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-first-quarter-2017-results-presentation-and-webcast-300458403.html

SOURCE Nordic Nanovector



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store